Logo

Janssen Oncology: Our purpose

Our purpose is to make cancer a manageable and, ultimately, curable condition. We understand that the power to change the lives of those with cancer begins with a very considered step forwards. Whether it’s from a passing conversation, a new indication approval, or even just reaching one more patient. It is about that promise of absolute dedication and commitment to innovation, finding new solutions, and listening to patients and healthcare professionals, so we can extend and improve the quality of life for those living with cancer. That’s The Power of Purpose®.

We fiercely believe cancer is a challenge we can collectively overcome. Find out more on our congress hub:

Please note, congress material is in parts promotional and is intended for European, Middle Eastern and African healthcare professionals only. Should you wish to proceed please enter login details.

For more than 30 years, we have been leaders in oncology research[1]

In that time, we have designed, developed and delivered treatments that change what it means to have, and to treat, cancer.[2][3][4][5][6][7] We have years of outstanding legacy in haematological malignancies and prostate cancer. In fact, in the last 7 years, we have launched five new oncology treatments in Europe.[2][3][4][5][6][8][9][10][11] What's more, we have four more treatments currently under investigation in phase III clinical trials.[12][13][14][15][16]

over a million cancer patients

Over a million cancer patients have been treated with our medicines worldwide.[17][18][19][20]

At Janssen Oncology, we are taking science from where it is to where it has never been before, through targeted transformation[21]

We recognise that every cancer is different, each possessing unique challenges along the way.[22] But we don’t try and solve all these challenges. We are precisely focused on mastering the areas where we can make the most meaningful difference.

Cancer brings devastation, but we are striving to make meaningful change. Find out more about our areas of focus:

Multiple myeloma

Bladder cancer

Prostate cancer

Lung cancer

Discover precisely focused information on:

The diagnosis and management of rare haematological malignancies: Waldenström's macroglobulinaemia and mantle cell lymphoma

The hidden threat of EGFR exon 20 insertion mutations in NSCLC and the importance of testing

Start seeing your patients' tumour drivers more clearly: the role of FGFR

Our first responsibility is to the patients suffering from cancer

Our first responsibility is to the patients suffering from cancer, wherever they are in their own personal journey

Worldwide in 2020 there were an estimated 19.3 million new cancer cases and 9.9 million deaths.[23] Cancer brings devastation. Patients, their families, and the entire oncology community deserve meaningful change. At Janssen Oncology, we consistently integrate their perspectives into everything we do. But we don’t just listen, we use insight to create solutions that make a truly meaningful difference.

We place people front and centre and are committed to delivering high quality medical education

To help us achieve this we are privileged to have the support and participation of internationally renowned experts who form our scientific committee and faculties. Their involvement ensures we continue to provide clinically relevant and balanced education.

To find out more about our solid tumour medical education hub, visit The OME Forum

To find out more about our haematology education hub, visit The HME Forum

EGFR, epidermal growth factor receptor. FGFR, fibroblast growth factor receptor. NSCLC, non-small cell lung cancer.

Date of preparation: June 2021 | CP-232494

References

[1]
Clinicaltrials.gov. Molecular Studies and Clinical Correlations in Human Prostatic Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT00578240. Accessed May 2021.
[2]
Apalutamide. Summary of Product Characteristics. April 2021.
[3]
Abiraterone acetate. Summary of Product Characteristics. December 2020.
[4]
Daratumumab. Summary of Product Characteristics. January 2021.
[5]
Ibrutinib. Summary of Product Characteristics. January 2021.
[6]
Decitabine. Summary of Product Characteristics. April 2019.
[7]
Bortezomib. Summary of Product Characteristics. October 2019.
[8]
Johnson & Johnson. Abiraterone acetateApproved In The European Union For Metastatic Castration-Resistant Prostate Cancer. Available at: https://bit.ly/3zpBPB1. Accessed May 2021.
[9]
Business Wire. Janssen Announces European Commission Approval for Expanded Use of Apalutamide for Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer. Available at: https://bwnews.pr/35gPGf6. Accessed May 2021.
[10]
PharmaPhorum. Janssen’s daratumumab approved in EU for newly-diagnosed multiple myeloma. Available at: https://bit.ly/3viesWF. Accessed May 2021.
[11]
European Pharmaceutical Review. Ibrutinib granted expanded use from European Commission. Available at: https://bit.ly/2TvwKXu. Accessed May 2021
[12]
Clinicaltrials.gov. Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301). Available at: https://clinicaltrials.gov/ct2/show/NCT04248829. Accessed May 2021.
[13]
Clinicaltrials.gov. A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (PAPILLON). Available at: https://clinicaltrials.gov/ct2/show/NCT04538664. Accessed May 2021.
[14]
Clinicaltrials.gov. A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA). Available at: https://clinicaltrials.gov/ct2/show/NCT04487080. Accessed May 2021.
[15]
Clinicaltrials.gov. A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE). Available at: https://clinicaltrials.gov/ct2/show/NCT03748641. Accessed May 2021.
[16]
Clinicaltrials.gov. A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations. Available at: https://clinicaltrials.gov/ct2/show/NCT03390504. Accessed May 2021.
[17]
Janssen. Data on file. FEP21 Patient-based models.
[18]
Janssen. Data on file (RF-145436). Daratumumab: New Patient Starts Launch to Date.
[19]
Janssen. Data on file (EMEA-SR-1492). Global number of cumulative patients treated with Ibrutinib since launch.
[20]
Janssen. Data on file. Number of patients treated with haematological malignancy treatments in 2020.
[21]
Johnson & Johnson. The Next Generation of Cancer Care: How Johnson & Johnson Is Working to Defeat—and Even Prevent—the Disease. Available at: https://www.jnj.com/innovation/how-johnson-and-johnson-is-working-to-defeat-and-prevent-cancer. Accessed June 2021.
[22]
Ogino S. et al. Expert Rev Mol Diagn. 2012; 12(6): 621–628.
[23]
IARC. All cancer fact sheet. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. Accessed May 2021.
© Janssen Pharmaceutica NV 2022. This site is published by Janssen Pharmaceutica NV which is solely responsible for its content. This site is intended for use by Healthcare Professionals in Europe, Middle East and Africa.
Cookie Settings
Logo